GR1802 not checked

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
8 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Recombinant fully human anti-IL4Rα monoclonal antibody drug.”In the company’s words, NCT07154342 on ClinicalTrials.gov
Tested for
Allergic Rhinitis, Seasonal (2 trials), Allergic Rhinitis
Main trialPhase 3
“Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.”In the company’s words, NCT07154342 on ClinicalTrials.gov

Other drugs for Allergic Rhinitis, Seasonal

All 11 drugs for Allergic Rhinitis, Seasonal

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Apr 2026 A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
Phase 3Not yet recruiting 15 May 2027 A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
Phase 2Active, not recruiting May 2025 A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
Phase 3Unknown Jun 2025 Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis
Phase 3Completed 12 Jun 2026 A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
Phase 2Unknown 30 Oct 2024 The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
Phase 2Unknown 30 Dec 2024 The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Phase 2Unknown 31 Mar 2025 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow GR1802

Following is part of Solo: you see every change to GR1802 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in